GeNeuro Announces Approval of all Resolutions Proposed at 2021 Annual General Meeting
- 75.88% of the Company’s share capital was represented at the AGM and resolutions were all widely approved
- Temelimab Phase II in MS on track to read-out in Q1 2022
- Continued development of temelimab clinical approaches against Acute COVID-19 and Post-COVID syndromes
GENEVA–(BUSINESS WIRE)–Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2021. These included among others:
- Approval of the annual report and accounts for the year ended 31 December 2020
- Re-election/election of the Chairman and all Members of the Board of Directors
- Approval of maximum aggregate Board of Directors and Managerial compensation for 2022
- Re-election of PricewaterhouseCoopers, Geneva, as auditors
75.88% of the Company’s share capital was represented at the AGM and resolutions were all widely approved. Detailed results are available on the Company’s website at: http://www.geneuro.com/en/investors/general-meetings.
Development update
GeNeuro remains committed to developing novel, safe and effective treatments against neurological disorders and autoimmune diseases by neutralizing causal factors encoded by Human Endogenous Retroviruses (HERV), which represent 8% of human DNA.
The Company’s main focus remains on MS, where its Phase II clinical trial of temelimab at the Karolinska Institutet/Academic Specialist Center of Stockholm is progressing well, fully recruited and on track to deliver results in Q1 2022.
The importance of HERVs in a growing number of diseases has recently been reinforced by the discoveries made by University of Rome “Tor Vergata” and the International Center for Infectiology Research (CIRI) in Lyon, which have brought to light the link between HERV-W ENV presence and the severity of COVID-19 disease. The documented pathogenicity of HERV-W ENV makes it a high-interest target against some of the most severe syndromes associated with COVID-19, both in acute and long-term settings. The interest in this approach was recently highlighted by Dr. Avindra Nath, Clinical Director of the US National Institute for Neurological Diseases and Stroke, in an editorial commentary to the article published in the Lancet’s EBioMedicine.
GeNeuro continues to work with leading centers in Europe and the USA to finalize its clinical approaches in acute COVID-19 and post-COVID syndromes, which could allow temelimab a fast access to market.
Forthcoming investor and industry events:
June 21-22, 2021: Gilbert Dupont Small & Midcaps Full Digital Forum
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
Disclaimer:
This press release contains certain forward – looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 48 00
[email protected]
NewCap (France)
Louis-Victor Delouvrier /
Mathilde Bohin (investors)
+33 1 44 71 98 52
Nicolas Merigeau (media)
+33 1 44 71 94 98
[email protected]
Halsin Partners
Mike Sinclair (media)
+44 7968 022075
[email protected]
LifeSci Advisors
Chris Maggos (investors)
+41 79 367 6254
[email protected]
